Refractory Clinical Trials in Atlanta, Georgia
60 recruitingAtlanta, Georgia
Showing 1–20 of 60 trials
Recruiting
Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Myelodysplastic SyndromesRelapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AML+1 more
Institut de Recherches Internationales Servier291 enrolled30 locationsNCT02074839
Recruiting
Phase 1
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome+6 more
National Cancer Institute (NCI)54 enrolled22 locationsNCT06484062
Recruiting
Phase 2
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic LeukemiaRefractory B Acute Lymphoblastic LeukemiaRecurrent B Lymphoblastic Lymphoma+1 more
Children's Oncology Group80 enrolled157 locationsNCT02981628
Recruiting
Phase 2
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
National Cancer Institute (NCI)20 enrolled7 locationsNCT07003295
Recruiting
Phase 1Phase 2
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
Relapsed and/or Refractory B-cell Lymphoma
Kite, A Gilead Company247 enrolled21 locationsNCT04989803
Recruiting
Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Recurrent B Acute Lymphoblastic LeukemiaB Acute Lymphoblastic Leukemia, Philadelphia Chromosome NegativeRefractory B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)84 enrolled276 locationsNCT03739814
Recruiting
Phase 3
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
Refractory Differentiated Thyroid Gland Carcinoma
ECOG-ACRIN Cancer Research Group264 enrolled301 locationsNCT06475989
Recruiting
Phase 1
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
Acute Leukemia of Ambiguous LineageRefractory Acute Myeloid LeukemiaRelapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital24 enrolled10 locationsNCT06177067
Recruiting
Phase 1Phase 2
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ovarian CarcinomaColorectal CarcinomaMelanoma+19 more
Children's Oncology Group147 enrolled21 locationsNCT04851119
Recruiting
Phase 1
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 1
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
Recurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Myelodysplastic SyndromeRecurrent Juvenile Myelomonocytic Leukemia+3 more
Children's Oncology Group36 enrolled19 locationsNCT06247787
Recruiting
Phase 2
Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
Stage III Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Advanced Lung Adenocarcinoma+1 more
Emory University50 enrolled3 locationsNCT06495125
Recruiting
Phase 1
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Acute Myeloid LeukemiaMyeloid SarcomaAcute Myeloid Leukemia, in Relapse+7 more
Kura Oncology, Inc.420 enrolled44 locationsNCT05735184
Recruiting
Phase 1
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer
OncoTherapy Science, Inc.70 enrolled8 locationsNCT02926690
Recruiting
Phase 1
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Relapsed or Refractory T Cell Lymphoma
Ono Pharmaceutical Co., Ltd.217 enrolled20 locationsNCT05079282
Recruiting
Phase 1
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome (MDS)Relapsed/Refractory Acute Myeloid Leukemia (AML)
Cullinan Therapeutics Inc.60 enrolled11 locationsNCT05143996
Recruiting
Phase 1Phase 2
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Beat AML, LLC3,000 enrolled19 locationsNCT03013998
Recruiting
Phase 1
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia
Nerviano Medical Sciences124 enrolled7 locationsNCT06549790
Recruiting
Phase 1Phase 2
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Chronic Myelomonocytic LeukemiaMyelodysplastic Syndrome With Excess Blasts-2Leukemia, Myeloid, Acute+2 more
Aptose Biosciences Inc.240 enrolled34 locationsNCT03850574
Recruiting
Phase 2
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
Emory University46 enrolled2 locationsNCT05039073